Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker RAPP
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | RAPP Rapport Therapeutics, Inc. | TRV GP VI, LLC | 969,218 | 2.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | RAPP Rapport Therapeutics, Inc. | Third Rock Ventures GP VI, L.P. | 969,218 | 2.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | RAPP Rapport Therapeutics, Inc. | Third Rock Ventures VI, L.P. | 969,218 | 2.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | RAPP Rapport Therapeutics, Inc. | TRV GP V, LLC | 6.28M | 13.1% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | RAPP Rapport Therapeutics, Inc. | Third Rock Ventures GP V, L.P. | 6.28M | 13.1% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | RAPP Rapport Therapeutics, Inc. | Third Rock Ventures V, L.P. | 6.28M | 13.1% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | RAPP Rapport Therapeutics, Inc. | Bihua Chen | 2.66M | 5.6% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | RAPP Rapport Therapeutics, Inc. | Cormorant Asset Management, LP | 2.66M | 5.6% | SCHEDULE 13G/A ↗ |
| Aug 12, 2026 | SCHEDULE 13G/A (amended) | RAPP Rapport Therapeutics, Inc. | Capital International Investors | 2.92M | 6.1% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | RAPP Rapport Therapeutics, Inc. | Bihua Chen | 2.96M | 6.2% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | RAPP Rapport Therapeutics, Inc. | Cormorant Asset Management, LP | 2.96M | 6.2% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | RAPP Rapport Therapeutics, Inc. | Bihua Chen | 3.03M | 6.3% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | RAPP Rapport Therapeutics, Inc. | Cormorant Asset Management, LP | 3.03M | 6.3% | SCHEDULE 13G/A ↗ |
| Jan 21, 2026 | SCHEDULE 13G | RAPP Rapport Therapeutics, Inc. | BlackRock, Inc. | 2.40M | 5.0% | SCHEDULE 13G ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | RAPP Rapport Therapeutics, Inc. | Bihua Chen | 3.19M | 6.7% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | RAPP Rapport Therapeutics, Inc. | Cormorant Asset Management, LP | 3.19M | 6.7% | SCHEDULE 13G/A ↗ |
| Oct 22, 2025 | SCHEDULE 13G/A (amended) | RAPP Rapport Therapeutics, Inc. | Johnson & Johnson Innovation - JJDC, Inc. | 1.78M | 4.9% | SCHEDULE 13G/A ↗ |
| Oct 22, 2025 | SCHEDULE 13G/A (amended) | RAPP Rapport Therapeutics, Inc. | Johnson & Johnson | 1.78M | 4.9% | SCHEDULE 13G/A ↗ |
| Sep 18, 2025 | SCHEDULE 13D/A (amended) | RAPP Rapport Therapeutics, Inc. | Dr. Maha Katabi ("Katabi") | 1.86M | 4.0% | SCHEDULE 13D/A ↗ |
| Sep 18, 2025 | SCHEDULE 13D/A (amended) | RAPP Rapport Therapeutics, Inc. | Dr. James I. Healy ("Healy") | 1.95M | 4.2% | SCHEDULE 13D/A ↗ |
| Sep 18, 2025 | SCHEDULE 13D/A (amended) | RAPP Rapport Therapeutics, Inc. | Sofinnova Management XI, L.L.C. ("SM XI LLC") | 1.86M | 4.0% | SCHEDULE 13D/A ↗ |
| Sep 18, 2025 | SCHEDULE 13D/A (amended) | RAPP Rapport Therapeutics, Inc. | Sofinnova Management XI, L.P. ("SM XI LP") | 1.86M | 4.0% | SCHEDULE 13D/A ↗ |
| Sep 18, 2025 | SCHEDULE 13D/A (amended) | RAPP Rapport Therapeutics, Inc. | Sofinnova Venture Partners XI, L.P. ("SVP XI") | 1.86M | 4.0% | SCHEDULE 13D/A ↗ |
| Feb 13, 2025 | SCHEDULE 13G | RAPP Rapport Therapeutics, Inc. | TRV GP VI, LLC | 969,218 | 2.7% | SCHEDULE 13G ↗ |
| Feb 13, 2025 | SCHEDULE 13G | RAPP Rapport Therapeutics, Inc. | Third Rock Ventures GP VI, L.P. | 969,218 | 2.7% | SCHEDULE 13G ↗ |
| Feb 13, 2025 | SCHEDULE 13G | RAPP Rapport Therapeutics, Inc. | Third Rock Ventures VI, L.P. | 969,218 | 2.7% | SCHEDULE 13G ↗ |
| Feb 13, 2025 | SCHEDULE 13G | RAPP Rapport Therapeutics, Inc. | TRV GP V, LLC | 7.14M | 19.5% | SCHEDULE 13G ↗ |
| Feb 13, 2025 | SCHEDULE 13G | RAPP Rapport Therapeutics, Inc. | Third Rock Ventures GP V, L.P. | 7.14M | 19.5% | SCHEDULE 13G ↗ |
| Feb 13, 2025 | SCHEDULE 13G | RAPP Rapport Therapeutics, Inc. | Third Rock Ventures V, L.P. | 7.14M | 19.5% | SCHEDULE 13G ↗ |
29 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 5:59 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances